Rapid Dose Therapeutics Management
Management criteria checks 3/4
Rapid Dose Therapeutics' CEO is Mark Upsdell, appointed in May 2017, has a tenure of 7.58 years. total yearly compensation is CA$150.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 9.35% of the company’s shares, worth $1.67M. The average tenure of the management team and the board of directors is 6.2 years and 1.7 years respectively.
Key information
Mark Upsdell
Chief executive officer
CA$150.0k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 7.6yrs |
| CEO ownership | 9.4% |
| Management average tenure | 6.2yrs |
| Board average tenure | 1.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Aug 31 2024 | n/a | n/a | -CA$5m |
| May 31 2024 | n/a | n/a | -CA$5m |
| Feb 29 2024 | CA$150k | CA$150k | -CA$4m |
| Nov 30 2023 | n/a | n/a | -CA$4m |
| Aug 31 2023 | n/a | n/a | -CA$3m |
| May 31 2023 | n/a | n/a | -CA$3m |
| Feb 28 2023 | CA$156k | CA$150k | -CA$4m |
| Nov 30 2022 | n/a | n/a | -CA$9m |
| Aug 31 2022 | n/a | n/a | -CA$10m |
| May 31 2022 | n/a | n/a | -CA$9m |
| Feb 28 2022 | CA$212k | CA$150k | -CA$8m |
| Nov 30 2021 | n/a | n/a | -CA$2m |
| Aug 31 2021 | n/a | n/a | -CA$2m |
| May 31 2021 | n/a | n/a | -CA$1m |
| Feb 28 2021 | CA$100k | CA$100k | -CA$2m |
| Nov 30 2020 | n/a | n/a | -CA$2m |
| Aug 31 2020 | n/a | n/a | -CA$5m |
| May 31 2020 | n/a | n/a | -CA$5m |
| Feb 29 2020 | CA$765k | CA$272k | -CA$8m |
| Nov 30 2019 | n/a | n/a | -CA$17m |
| Aug 31 2019 | n/a | n/a | -CA$15m |
| May 31 2019 | n/a | n/a | -CA$14m |
| Feb 28 2019 | CA$344k | CA$292k | -CA$11m |
| Nov 30 2018 | n/a | n/a | -CA$3m |
| Aug 31 2018 | n/a | n/a | -CA$2m |
| Feb 28 2018 | CA$412k | CA$341k | -CA$2m |
Compensation vs Market: Mark's total compensation ($USD104.28K) is below average for companies of similar size in the US market ($USD653.16K).
Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.
CEO
Mark Upsdell
7.6yrs
Tenure
CA$150,000
Compensation
Mr. Mark Andrew Upsdell is the Chief Executive Officer and Director of Rapid Dose Therapeutics Corp. since May 03, 2017 and he served as its Chairman. He serves as President of Rapid Dose Therapeutics Corp...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 7.6yrs | CA$150.00k | 9.35% $ 1.7m | |
| Chief Financial Officer | 4.8yrs | CA$157.75k | no data | |
| Senior VP of Business Development & Director | 7.6yrs | CA$150.00k | no data | |
| Chief Scientist | 1.3yrs | no data | no data | |
| Legal Counsel | no data | no data | no data | |
| Controller | no data | no data | no data | |
| Assistant Corporate Secretary | no data | no data | no data |
6.2yrs
Average Tenure
Experienced Management: RDTC.F's management team is seasoned and experienced (6.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 7.6yrs | CA$150.00k | 9.35% $ 1.7m | |
| Senior VP of Business Development & Director | less than a year | CA$150.00k | no data | |
| Independent Director | 1.7yrs | CA$17.49k | 0.54% $ 95.8k | |
| Independent Director | 4.3yrs | CA$47.41k | 0.11% $ 19.3k | |
| Member Medical of Advisory Board | 2.9yrs | no data | no data | |
| Independent Director | 1.3yrs | CA$17.49k | 0.051% $ 9.1k | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Independent Director | 1.3yrs | CA$17.49k | no data | |
| Member of Medical Advisory Board | 3yrs | no data | no data | |
| Independent Director | less than a year | CA$17.49k | 0.44% $ 77.9k |
1.7yrs
Average Tenure
Experienced Board: RDTC.F's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 12:39 |
| End of Day Share Price | 2024/12/11 00:00 |
| Earnings | 2024/08/31 |
| Annual Earnings | 2024/02/29 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Rapid Dose Therapeutics Corp. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter-Thilo Hasler | Sphene Capital GmbH |